Last reviewed · How we verify
Dalgan (DEZOCINE)
At a glance
| Generic name | DEZOCINE |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | dezocine |
| Target | Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1989 |
Approved indications
- Pain
Common side effects
Key clinical trials
- Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial. (NA)
- Effectiveness and Safety of Adjuvant Software Based on Virtual Reality for Post-thoracoscopic Surgery Pain (NA)
- Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery (PHASE4)
- Rhomboid Intercostal and Subserratum Plane Block for Minimally Invasive Esophagectomy (NA)
- The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy (NA)
- The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser (PHASE4)
- Dezoxide Suppresses Sufentanil-induced Cough (NA)
- Use of Oxycodone in Bariatric Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dalgan CI brief — competitive landscape report
- Dalgan updates RSS · CI watch RSS
- AstraZeneca portfolio CI